Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Princess Margaret Hospital
Toronto, Ontario, Canada
- Mayo Clinic Hospital
Phoenix, Arizona, United States
- Ucsf
San Francisco, California, United States
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Dana Farber Cancer Center
Boston, Massachusetts, United States
- Mayo
Rochester, Minnesota, United States
- Tristar Cmc
Nashville, Tennessee, United States
- Ut Southwestern Medical Center
Dallas, Texas, United States
- Md Anderson
Houston, Texas, United States
- Methodist Hosptial
Houston, Texas, United States
- Huntsman Cancer Center
Salt Lake City, Utah, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Sept 2019
- Primary completion
- 31 Dec 2024
- Completion
- 31 Dec 2034
- Last update posted
- 19 Dec 2023
- Registered enrollment
- 105
- Registry id
- NCT03915184
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.